Pharma

Vedanta’s Live Bacteria Cocktail Fails Phase 2 Ulcerative Colitis Trial

While VE202 misses efficacy endpoint, strong safety profile underscores potential of microbiome-based therapies; company doubles down on Phase 3 trial in recurrent C. difficile.

Eli Lilly's Oral GLP-1 Candidate Orforglipron Shows 12% Weight Loss in Pivotal Trial, Eyes Regulatory Filing

Phase 3 data show modest efficacy for Lilly's once-daily oral GLP-1, positioning it as a convenient but less potent rival to injectable obesity drugs.

Antibodies.com Supercharges UK Operations with Move to Larger Cambridge HQ

Antibodies.com has moved to a new, five-times-larger headquarters at Cambridge Technopark to support rapid growth and better serve life science researchers worldwide.

Compass Pathways' Phase 3 Psilocybin Readout Raises Efficacy Questions Despite Meeting Primary Endpoint

Investor skepticism underscores challenges in demonstrating robust clinical value in psychedelic therapeutics for depression.

Novo Nordisk Strikes $812 Million Deal with Deep Apple Therapeutics to Strengthen Obesity Pipeline

The Wegovy maker announces strategic agreement worth up to $812 million with Deep Apple Therapeutics, continuing their aggressive investment into its obesity drug pipeline.

Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Receives Marketing Authorization in Australia

Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has been approved in Australia for treating early-stage Alzheimer’s disease in patients with confirmed amyloid pathology.